A New Paradigm to Address Age-Related Diseases
Portera Therapeutics is pioneering a new frontier in targeted protein degradation—focused on intrinsically disordered proteins (IDPs) implicated in Parkinson’s, ALS, and Alzheimer’s Disease.
Our Approach
Pipeline in an Asset Targeting Degradation of Disordered Proteins
Portera’s small molecules are purpose-built to target proteins that lack defined structure (intrinsically disordered proteins) and play a central role in neurodegenerative diseases, e.g. α-synuclein in Parkinson’s Disease.
Our 20S proteasome enhancers precisely bind, potentiate, and drive the degradation of these elusive, unstructured targets. The result: a new therapeutic modality aimed at the root causes of previously untreatable diseases.
Our Team
Built by Scientists. Backed by Dedication.
Portera brings together proven scientific leadership and seasoned biotech operators. Our founding science originates from Michigan State University and the University of Virginia, and is guided by pioneers in chemistry, neurodegeneration, and drug development.